Replies to post #25591 on Viropro, Inc. (VPRO)

[Alphavol]

With a better business model, an attractiver pipeline than similar company Juno Therapeutics. A few months ago Juno was even worth $6bn mcap. We do have enough information Axxiom has the potential to get there, upon confirmation (Merger, other LOIs, Nasdaq, etc.) your stake will be worth $3+. Other elements such as short covering, tight free float will help. Go VPRO/Axxiom

[Alphavol]

What do you think of the following:

-Juno Therapeutic: marketcap $2.7bn. Pipeline:
https://junotherapeutics.com/pipeline/

-Viropro/Axxiom/NovaRx: marketcap $21M. Pipeline:
http://www.novarx.com/pipeline.html

Very similar companies, Axxiom/NovaRx Phase III trial also in the starting block. Don t you think something huge is to take place Shortly? Nasdaq investors love such stories.
Go VPRO